Table 1 Baseline characteristics grouped by bone marrow remission levels on day 28 of venetoclax

From: Remission rate, toxicity and pharmacokinetics of venetoclax-based induction regimens in untreated pediatric acute myeloid leukemia

Variables

Total (n = 45)

CR/Cri (n = 39)

PR/NR (n = 6)

P1

MRD(−) (n = 20)

MRD(+) (n = 25)

P2

Age (years), median (range)

9.3 (0.9–15.8)

9.9 (0.9–15.8)

3.2 (0.9–14.7)

0.129

9.6 (0.9–14.6)

9.3 (0.9–15.8)

0.681

Sex, n (%)

0.929

  

0.540

 male

27 (60.0)

24 (61.5)

3 (50.0)

 

11 (55.0)

16 (64.0)

 

 female

18 (40.0)

15 (38.5)

3 (50.0)

 

9 (45.0)

9 (36.0)

 

WBC count, n (%)

   

0.529

  

0.791

 <100×109/L

40 (88.9)

35 (89.7)

5 (83.3)

 

17 (85.0)

23 (92.0)

 

 >100×109/L

5 (11.1)

4 (10.3)

1 (16.7)

 

3 (15.0)

2 (8.0)

 

Risk stratification, n (%)

   

0.359

  

0.345

 low/middle

19 (42.2)

18 (46.2)

1 (16.7)

 

10 (50.0)

9 (36.0)

 

 high

26 (57.8)

21 (53.8)

5 (83.3)

 

10 (50.0)

16 (64.0)

 

sAML, n (%)

7 (15.6)

4 (10.3)

3 (50.0)

0.039

3 (15.0)

4 (16.0)

1.000

Myeloid sarcoma, n (%)

3 (6.7)

3 (7.7)

0 (0.0)

1.000

1 (5.0)

2 (8.0)

1.000

CNS leukemia, n (%)

2 (4.4)

1 (2.6)

1 (16.7)

0.252

1 (5.0)

1 (4.0)

1.000

Testicular leukemia, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

-

0 (0.0)

0 (0.0)

-

Morphological typing, n (%)

   

0.004

  

0.453

 M2

18 (40.0)

18 (46.2)

0 (0.0)

 

8 (40.0)

10 (40.0)

 

 M2/M4

3 (6.7)

3 (7.7)

0 (0.0)

 

2 (10.0)

1 (4.0)

 

 M4

6 (13.3)

6 (15.4)

0 (0.0)

 

4 (20.0)

2 (8.0)

 

 M5

5 (11.1)

5 (12.8)

0 (0.0)

 

3 (15.0)

2 (8.0)

 

 M7

4 (8.9)

2 (5.1)

2 (33.3)

 

1 (5.0)

3 (12.0)

 

 Not available

9 (20.0)

5 (12.8)

4 (66.7)

 

2 (10.0)

7 (28.0)

 

Genetics, n (%)

      

 FLT3 mutation(+)

12 (26.7)

11 (28.2)

1 (16.7)

0.921

6 (30.0)

6 (24.0)

0.651

 AML1-ETO(+)

10 (22.2)

10 (25.6)

0 (0.0)

0.379

3 (15.0)

7 (28.0)

0.496

 WT1(+)

8 (17.8)

7 (17.9)

1 (16.7)

1.000

5 (25.0)

3 (12.0)

0.459

 MLL rearrangement(+) (except for MLL-AF9)

7 (15.6)

5 (12.8)

2 (33.3)

0.230

3 (15.0)

4 (16.0)

1.000

 NRAS(+)

5 (11.1)

5 (12.8)

0 (0.0)

1.000

2 (10.0)

3 (12.0)

1.000

 C-KIT(+)

5 (11.1)

5 (12.8)

0 (0.0)

1.000

3 (15.0)

2 (8.0)

0.791

 RUNX1(+)

4 (8.9)

4 (10.3)

0 (0.0)

1.000

1 (5.0)

3 (12.0)

0.770

 CEBPA double mutation(+)

4 (8.9)

4 (10.3)

0 (0.0)

1.000

2 (10.0)

2 (8.0)

1.000

 KRAS(+)

3 (6.7)

2 (5.1)

1 (16.7)

0.356

1 (5.0)

2 (8.0)

1.000

 MLL-AF9(+)

2 (4.4)

1 (2.6)

1 (16.7)

0.252

1 (5.0)

1 (4.0)

1.000

 NUP98 rearrangement(+)

2 (4.4)

2 (5.1)

0 (0.0)

1.000

2 (10.0)

0 (0.0)

0.192

 TP53(+)

0 (0.0)

0 (0.0)

0 (0.0)

-

0 (0.0)

0 (0.0)

-

Chromosomal abnormalities, n (%)

 Complex karyotype

4 (8.9)

2 (5.1)

2 (33.3)

0.08

0 (0.0)

4 (16.0)

0.178

 -7/7q-

1 (2.2)

1 (2.6)

0 (0.0)

1.000

0 (0.0)

1 (4.0)

1.000

Therapy protocols, n (%)

   

0.309

  

0.641

 VEN + LDAC

6 (13.3)

5 (12.8)

1 (16.7)

 

3 (15.0)

3 (12.0)

 

 VEN + HA

27 (60.0)

25 (64.1)

2 (33.3)

 

10 (50.0)

17 (68.0)

 

 VEN + AZA

10 (22.2)

8 (20.5)

2 (33.3)

 

6 (30.0)

4 (16.0)

 

 VEN + DEC

2 (4.4)

1 (2.6)

1 (16.7)

 

1 (5.0)

1 (4.0)

 

Duration of VEN (day), median (range)

18 (9–28)

19 (9–28)

14 (10–28)

0.338

19 (10–28)

18 (9–28)

0.725

  1. 1grouping is based on the different levels of morphologic remission status on day 28 of venetoclax; 2grouping is based on the different levels of immunologic residual status on day 28 of venetoclax; quantitative variables are presented as medians (ranges); qualitative variables are presented as numbers (percentages).
  2. CR complete remission, CRi CR with incomplete hematologic recovery, NR nonremission, PR partial remission, MRD measurable residual disease, VEN venetoclax, LDAC low-dose cytarabine, AZA/DEC azacitidine/decitabine, HA homoharringtonine plus cytarabine, WBC white blood cell, sAML secondary AML, CNS central nervous system.
Back to article page